ArticleAnimal bioscience2026
Dose-dependent effects of a recombinant gonadotropin-releasing hormone vaccine on reproductive function and growth performance in male goats.
Article in Animal bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveThis study aimed to develop a recombinant gonadotropin-releasing hormone (GnRH) vaccine and to investigate the effects of different immunization doses on immunocastration efficacy and growth performance in male goats; thererby providing an animal welfare-friendly alternative to surgical castration (SC).
methodsForty male goats were randomly assigned to four groups (n = 10 per group): the saline-injected control (NC), SC, low-dose vaccine (LD), and high-dose vaccine (HD). The vaccine was given in accordance with a regular immunization protocol. Anti-GnRH antibody titers, serum testosterone concentrations, libido scores, histological characteristics of testicular tissues, and growth performance were measured to assess immunocastration efficacy.
resultsBoth LD and HD groups exhibited significantly higher anti-GnRH antibody titers than the NC group (p<0.01). Serum testosterone concentrations and libido scores were markedly reduced in the immunized groups (p<0.01), indicating effective suppression of reproductive function. Histological and quantitative analyses demonstrated pronounced testicular atrophy in immunocastrated goats, characterized by a significant reduction in seminiferous tubule diameter and spermatogenic cell number, as well as the absence of spermatozoa within the lumen. Although only limited time points showed significant differences between the two immunization doses, the overall immunocastration efficacy of the low- and high-dose regimens was largely comparable, with the low-dose group exhibiting slightly stronger suppression in certain parameters or time points. Additionally, immunocastrated goats had significantly higher body weight and weight gain compared to surgically castrated goats (p<0.01), while differences with the NC group were not significant (p>0.05).
conclusionThe recombinant GnRH vaccine effectively suppresses reproductive function in male goats. Compared with SC, immunocastration was associated with improved growth performance, while no significant differences were observed relative to intact animals. These findings support immunocastration as a non-invasive and animal-friendly alternative to SC in livestock production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.